Biotechnology
Technology
Health

BioMarin

$81.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.04%) Today
$0.00 (0.00%) As of 4:27 PM EDT after-hours

Why Robinhood?

You can buy or sell BioMarin and other stocks, options, ETFs, and crypto commission-free!

About BMRN

BioMarin Pharmaceutical Inc. Common Stock, also called BioMarin, is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Read More Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Employees
2,849
Headquarters
San Rafael, California
Founded
1997
Market Cap
14.60B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.11M
High Today
$82.49
Low Today
$80.99
Open Price
$81.93
Volume
700.93K
52 Week High
$106.74
52 Week Low
$79.13

Collections

Biotechnology
Technology
Health
Pharmaceutical
Medical
US
North America

BMRN News

Yahoo FinanceJun 24

BioMarin Gets $15M From Pfizer on Talzenna's European Nod

108
Yahoo FinanceJun 21

BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

77

BMRN Earnings

-$0.32
-$0.20
-$0.09
$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 1, After Hours

More BMRN News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.